Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Autism Spectrum Disorder in Children: Safety Profile and Effect on Cytokine Levels
Authors:
Open Access
- 11 June 2019
- journal article
- retracted article
- Published by Oxford University Press (OUP) in Stem Cells Translational Medicine
- Vol. 8 (10) , 1008-1016
Abstract
Individuals with autism spectrum disorder (ASD) suffer from developmental disabilities that impact communication, behavior, and social interaction. Immune dysregulation and inflammation have been linked to children with ASD, the latter manifesting in serum levels of macrophage‐derived chemokine (MDC) and thymus, and activation‐regulated chemokine (TARC). Mesenchymal stem cells derived from umbilical cord tissue (UC‐MSCs) have immune‐modulatory and anti‐inflammatory properties, and have been safely used to treat a variety of conditions. This study investigated the safety and efficacy of UC‐MSCs administered to children diagnosed with ASD. Efficacy was evaluated with the Autism Treatment Evaluation Checklist (ATEC) and the Childhood Autism Rating Scale (CARS), and with measurements of MDC and TARC serum levels. Twenty subjects received a dose of 36 million intravenous UC‐MSCs every 12 weeks (four times over a 9‐month period), and were followed up at 3 and 12 months after treatment completion. Adverse events related to treatment were mild or moderate and short in duration. The CARS and ATEC scores of eight subjects decreased over the course of treatment, placing them in a lower ASD symptom category when compared with baseline. MDC and TARC inflammatory cytokine levels also decreased for five of these eight subjects. The mean MDC, TARC, ATEC, and CARS values attained their lowest levels 3 months after the last administration. UC‐MSC administration in children with ASD was therefore determined to be safe. Although some signals of efficacy were observed in a small group of children, possible links between inflammation levels and ASD symptoms should be further investigated. Stem Cells Translational Medicine 2019Keywords
Funding Information
- Translational Biosciences
This publication has 56 references indexed in Scilit:
- Decreased transforming growth factor beta1 in autism: A potential link between immune dysregulation and impairment in clinical behavioral outcomesJournal of Neuroimmunology, 2008
- Gastrointestinal Symptoms in a Sample of Children with Pervasive Developmental DisordersJournal of Autism and Developmental Disorders, 2008
- Stem Cell Therapy for AutismJournal of Translational Medicine, 2007
- The immune response in autism: a new frontier for autism researchJournal of Leukocyte Biology, 2006
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006
- Intestinal Lymphocyte Populations in Children with Regressive Autism: Evidence for Extensive Mucosal ImmunopathologyJournal of Clinical Immunology, 2003
- Prevalence of Chronic Gastrointestinal Symptoms in Children with Autism and Autistic Spectrum DisordersAutism, 2003
- Autism and gastrointestinal symptomsCurrent Gastroenterology Reports, 2002
- Repeated Doses of Porcine Secretin in the Treatment of Autism: A Randomized, Placebo-Controlled TrialPediatrics, 2001
- Efficacy of Methylphenidate Among Children with Autism and Symptoms of Attention-Deficit Hyperactivity DisorderJournal of Autism and Developmental Disorders, 2000